Modificare „Catalyst Biosciences Inc”

Pagina dedicata companiei Catalyst Biosciences Inc listata cu simbolul US.CBIO

==Descriere companie==
Catalyst Biosciences, Inc.(www.catalystbiosciences.com) formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.CBIO" />

==Ultimele stiri despre Catalyst Biosciences Inc (US.CBIO)==
<dynamicpagelist>
category=US.CBIO
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.CBIO]][[Categorie:Stiri despre companii]]